Nanoscale Drug Delivery Systems in Glioblastoma

Zihao Liu1, Xiaoshuai Ji2, Dong He1, Rui Zhang1, Qian Liu4* and Tao Xin2,3,5*

Abstract
Glioblastoma is the most aggressive cerebral tumor in adults. However, the current pharmaceuticals in GBM treatment are mainly restricted to few chemotherapeutic drugs and have limited efficacy. Therefore, various nanoscale biomaterials that possess distinct structure and unique property were constructed as vehicles to precisely deliver molecules with potential therapeutic effect. In this review, nanoparticle drug delivery systems including CNTs, GBNs, C-dots, MOFs, Liposomes, MSNs, GNP, PMs, Dendrimers and Nanogel were exemplified. The advantages and disadvantages of these nanoparticles in GBM treatment were illustrated.

Keywords: Glioblastoma, Nanoparticles, Biomaterials, Drug delivery systems

Introduction
Glioblastoma, also called glioblastoma multiforme (GBM), is considered as the most aggressive cerebral tumor in adults. The standard therapy for GBM is maximal safe resection followed by adjuvant radiation and oral temolozomide (TMZ), which extends patients’ life expectancy only by 16 to 18 months [1]. Due to the aggressive and invasive characteristics of GBM, resecting all tumor tissues in surgery is acknowledged to be impractical. Additionally, extensive resistance can be easily induced after long-term radiotherapy and chemotherapy treatments. The high phenotypic and genotypic heterogeneity of GBM result in multidrug resistance and limited specificity for drug delivery. The bioavailability and efficacies of delivered therapeutic drugs are mainly impaired by factors including tumor microenvironment, stem cell, immune escape, and the most importantly, Blood–Brain Barrier (BBB).

Nanotechnology is an interdisciplinary science to develop and investigate materials at nanometer scale. Disciplines such as physics, chemistry, engineering and biomedical are involved in, hence nanotechnology has become an emerging field in recent years. Although the sensu stricto description of nanotechnology is defined as the manipulation of matters from 1 to 100 nm (by National Nanotechnology Initiative), researchers prefer to recognize it with the broad range to hundreds of nanometers (in submicron scale), especially in the biomedical field. With the remarkable advancements in nanotechnology, nanomaterials were translated into the biomedical area and numerous nanoparticles (NPs) have been developed as drug delivery systems (DDS) for diagnostic and therapeutic application. Based on their different action modes, nanoscale DDS can be classified as passive targeting or active targeting systems. The passive targeting DDS exploit the signatures of tumoral angiogenesis, in which the new blood vessels have enhanced permeability, and the poor lymphatic drainage can passively cause NPs retention (EPR effect). However, due to the existence of intact Blood–Brain Barrier, passive targeting DDS that lack selectivity are unable to penetrate into brain effectively and are unsuited to the GBM treatment. Therefore, active targeting DDS modified with vectors including peptide,
protein, aptamer, small molecule and hybrid membrane are utilized in GBM therapy to improve the effectiveness of delivered drugs [2].

Active targeting nanoscale drug delivery systems are able to overcome the limitations of conventional medication therapy. Blood–Brain Barrier is established between cerebral capillaries and neuroglia cells. The tight junctions between endothelial cells selectively restrict the paracellular diffusion of more than 98% particular small molecules including chemotherapy drugs and other therapeutic molecules [3]. The insufficient drug concentration in GBM local will lead to inferior therapeutic efficacy, yet several strategies for NPs bi-modification were employed to enhance the infiltration ability of drug platform. By utilizing Receptor-mediated Endocytosis (RME) process, drug-encapsulated NPs that conjugated to the paired ligands on brain endothelial cells could obtain significantly enhanced BBB permeability [4, 5]. Cationic-joint [6] and lipophilic [7, 8] NPs could effectively transport drugs into the brain through Adsorptive-mediated Endocytosis (AME) and transcellular lipophilic pathway, respectively. Besides, Carrier-mediated Endocytosis (CME) involving nutrient transporters [9] was utilized for effective delivery of nanoscale DDS. Hybrid cell membrane-coated NPs [10] could cross the intact BBB via Cell-mediated transport. Comparing to conventional drug administration routine, modified NPs delivery have the advantages of superior pharmacokinetic performance and high specificity. Prolonged half-time, reduced uptake by reticuloendothelial system and sustained drug release in tumor sites could reduce the delivery dosage and minimize side effects. Smart biomaterials were also employed to achieve specific bio-mechanical application and controlled drug release, in which environmental stimulants such as pH [11], temperature [12] and near-infrared (NIR) light [13] were exploited. Co-delivery of dual/multiple therapeutic molecules by NPs could be utilized to overcome multidrug resistance and the shortcomings of monotherapy. In addition, nanoscale DDS could be applied in surgical implantation [14], transdermal delivery [15], intranasal delivery [16] and ocular delivery [17]. Several NPs including Gliadel®, Doxil®, Lupron Depot®, Marqibo® were approved by Food and Drug Administration (FDA) in clinic applications for various diseases.

In this review, we focused on the nanoscale drug delivery systems that have been proposed for the diagnostics and therapeutics of glioblastoma. The synthesis, functionalization and application of NPs were discussed. The advantages and limitation of each nanoparticle were elaborated thoroughly. Finally, the prospect of future GBM nanoscale DDS therapy was discussed.

**Carbon Allotropes**

Carbon Nanotubes

Carbon nanotubes (CNTs) were recognized as the seamless cylindrical-shape materials with high aspect ratio and satisfactory penetration capacity [18]. CNT has emerged as an influential material in the mechanical and electrical area. They are classified into two structural types: single-walled CNTs (SWCNTs) and multi-walled CNTs (MWCNTs) (Fig. 1). SWCNTs are composed of a single cylindrical graphene sheet with diameter ranging from 0.4 to 2 nm [19]. MWCNTs are multilayer coaxial graphene sheets that encircle an inner cylinder. The outer diameter of MWCNTs ranges from 2 to 100 nm [20]. Although CNTs possess extraordinary properties such as high drug loading efficacy and photoluminescence, limitations including low solubility in aqueous solvent and short half-life impede their applications in life system. Researches [21, 22] indicated that the original CNTs showed inherently toxicity to organism irrespective of the preparation. Functionalization is acknowledged to be an effective approach to improve the dispersion and biocompatibility of CNTs. For instance, by involving hydrophilic groups/polymers, the poor solubility and bio-distribution of CNTs can be significantly improved. The major functionalization of CNTs includes oxidation, acylation, cycloaddition and noncovalent associations, in which the toxicity could be reduced [20]. Consequently, CNTs were exploited as an ideal vehicle for drug delivery in recent years due to the facilely modified features and stability. The advantages and disadvantages of CNTs as drug delivery system were listed in Table 1.

By modified with functionalized groups and polymers on surface, CNTs garnered superior properties such as hydrophilicity, biocompatibility and specificity. Samuel et al. [24] designed chemical functionalized nitrogen-doped MWCNT by acid treatment. The products N-MWCNT-ox specifically eliminated RG2 cells through DNA damage and oxidative stress without inducing reactive inflammation or systemic toxicity. In addition, the combination of N-MWCNT with TMZ exhibited additive tumor-suppressive effects on GBM. Although immunostimulatory oligonucleotide CpG was considered to activate TLR9 as well as initiate immune system to counteract GBM, its efficiency was proved disappointing in vivo. Darya et al. [25] integrated CpG with SWCNT non-covalently, which assisted the delivery of CpG without affecting its therapeutic properties. They demonstrated that SWCNT/CpG inhibited the migration of GBM cells by inducing TLR9/ NF-kB pathway of macrophages. In another efforts, chemotherapeutics including Carmustine [26], Oxaliplatin [27], Lucanthone [28] and Dasatinib [29] were encapsulated into the functionalized CNTs for GBM treatment. Evidences suggested that
N-CNTs/Carmustine [26] exhibited continuous kinetic release for 72 h, contributing to the increased intratumoral drug concentration and limited systemic toxicity when comparing with conventional administration route. Besides, TAT-PEI-B-MWCNT-COOH-Oxaliplatin [27] and f-MWNT-ANG [30] showed significantly enhanced BBB penetration and GBM targeting properties in animal model. Therefore, in order to effectively utilize CNTs as drug carriers, the surface modification is an indispensable part.

Graphene-Based Nanoparticles (GBNs)

Graphene is recognized as the two-dimensional sp² hybridized carbon material that assembles tightly in a honeycomb-like lattice structure. It has been widely employed in electronic devices (sensor, battery and transistor), aerospace and composite materials. Technically, graphene is recognized as the basic building blocks of other carbon materials such as CNTs and quantum dot [31]. Graphene materials possess excellent optical, electrical as well as mechanical properties and they have emerged as the revolutionary materials in nanoscale processing, biomedicine and drug delivery area. In respect of the physical features, graphene is well known for its exceptional stability, well diathermancy, high mechanical strength and great electrical conductivity. The common derivatives of GBNs are graphene oxides (GO) and reduced graphene oxides (rGO) (Fig. 2). They possess superior biocompatibility and straightforward bio-functionalization capacity [32] when comparing to carbon allotrope CNTs. Additionally, the unique photothermic property of GBNs can be utilized in the stimuli-responsive drug release [33].

The planar structure of GBNs provide large surface for the chemical conjugation of drugs or molecules [35]. Cationic glycoprotein Lactoferrin (Lf) belongs to the transferrin family which can be associated with the Lf receptor overexpressed on BBB endothelia cells. Therefore, the Lf-modified drug delivery systems were commonly utilized to across BBB through receptor-mediated endocytosis [36]. Song et al. [37] decorated GO with Lactoferrin and Fe₃O₄ to construct super-paramagnetic drug-loaded nanocomposite Lf@GO@Fe₃O₄@DOX (Doxorubicin). The NPs performed admirable DOX delivery efficiency as well as exceptional anti-tumor capacity. Similarly, peptide angiopept (ANG)-2 is a specific ligand for the low-density lipoprotein receptor-related protein-1 (LRP-1) expressed on BBB endothelia cells. ANG@GO@DOX designed by Zhao et al. [38] displayed enhanced intracellular uptake and cytotoxicity due to the specific endocytosis capacity. In addition, functionalized GO such as PF127@GO@DOX [39], FA@GO@TMZ [40], PLGA@GO@IUdR [41] and mAb@GO@PPa [42] showed promising therapeutic efficacies, indicating functionalization could significantly improve the BBB transport and GBM specificity.
Carbon dots (C-dots)
Carbon dots, which is also recognized as carbon quantum dots (CQDs), are composed of dispersed spherical carbon particles (graphite-like core and amorphous oxygen-containing shell) with small size below 10 nm [43]. The synthetic materials of CQDs were readily available, and the synthesis methods of CQDs are multifarious, which are generally based on “top-down” or “bottom-up” approaches [44]. Carbon dots possess unique photoluminescence (PL) properties, hence they are promising nanoparticles for imaging, photocatalysis and photovoltaics applications [45]. In addition, owing to the plentiful functional groups for branching and decorating, C-dots became one of the prominent drug delivery systems in GBM therapy.

The single chemotherapeutic drug administration may easily induce resistance and relapse of GBM after long-term employment. Researches [46, 47] focused on dual drug delivery were conducted to surmount the single drug delivery dilemma, however, the overall particle sizes of NPs are too large to across BBB. Sajini et al. [48] developed a triple conjugated system of C-dots with an average particle size of 3.5 nm, in which transferrin, epirubicin and temozolomide were associated. The triple conjugated system exerted intense cytotoxicity to GBM cells and displayed synergistic effects owing to the dual-drug combination. Wang et al. [49] designed the polymer-coated CODs with DOX and IL-6P7 (IL-6 fragment peptide for targeting). Based on the photoluminescence property of special CODs, fluorescence resonance energy transfer (FRET) effect were able to be induced by specific wavelength for DOX release real-time monitoring. In acidic solutions, the drug-encapsulated CODs exhibited increased DOX release similarly with other carbon
This pH-sensitive releasing performance attributed to the acid-induced protonation of NH₂ group in DOX and consequent dissociation of π-π interaction [50]. Piumi et al. [51] conjugated Gemcitabine and transferrin protein with CODs for pediatric GBM treatment, in which the outstanding BBB penetration, selective targeting as well as anti-GBM efficacy were observed.

Apart from CNTs, GBNs and CODs, other carbon nanostructures like fullerene and nanodiamond (ND) were also exploited for GBM drug delivery. The DDS based on carbon allotropes including CF@LYS@TEG@MMF [52], ND@DOX [53] (via convection-enhanced delivery) and Polyglycerol@ND@DOX [54] were reported in corresponding anti-GBM investigations. With respect to these carbon allotropic NPs, their biocompatibility and toxicity are greatly depended on the layer number, lateral size, hydrophilicity, and the most importantly, surface chemistry [31]. Hence, proper comprehension of how carbon NPs interact with cells is of significance to improve the biocompatibility and specificity through functionalization.

**Metal–Organic Frameworks (MOFs)**

Metal–organic frameworks, the synthetic nanomaterials with mesoporous structure and prominent surface area (1000–14,000 m²/g), are consisted of metal core and coordinated organic ligands [55]. The history of two-dimensional MOFs went back to 1897, when Hofmann [56] fabricated the first hybrid networks of nickel-organic crystal. MOFs were concerned to have pH-sensitive properties and tunable structures (pore size), therefore plenty of them were prepared as ideal drug delivery system. However, the non-biodegradable metal ions including iron, copper, cobalt, cadmium and nickel in MOFs could show potential toxicity to organism [57]. Materials of Institute Lavoisier (MILs) [58], Zeolitic Imidazolate Frameworks (ZIFs) [59], pDBI [60], Hong Kong University of Science and Technology (HKUST-1) [61], University of Oslo (UiOs) [62] and Isoreticular Metal Organic Frameworks (IRMOFs) [63] (Fig. 3) were widely applied in cancer drug delivery, among which ZIF-8 were the most eximious one in GBM investigation.

ZIF-8 is composed of central tetrahedral zinc and coordinated 2-methylimidazole at an angle of 145° [66]. The self-assemble lamellar structure of ZIF-8 was maintained by π-π stacking interaction and hydrogen bonds [66], resulting in the mesoporous cavity and large surface area of ZIF-8. With respect to biocompatibility, zinc represents the second most abundant metal in human, exerting nearly no potential metal cytotoxicity on human cells. Abhijeet et al. [67] developed LND-HA@ZIF-8@Lf@5-FU nanoparticles, in which hyaluronic acid (HA) targeted the CD44 receptors overexpressed on GBM cells, and Lf endowed NPs with BBB penetrating ability. In addition, chemotherapeutics Lenalidomide (LND) and 5-Fluorouracil (5-FU) exerted anti-GBM function in a synergetic manner. Pan et al. [68] produced bimetallic Mn-ZIF-8 aiming to deliver 5-FU. Due to the excessive glycolysis of Warburg effect, pH-sensitive Mn²⁺ and 5-FU were easily released in the relatively acidic GBM microenvironment. Meanwhile, the accumulation of Mn²⁺ in GBM provided available T₁-weighted MR signals for in vivo imaging, enabling NPs to exert diagnostic and therapeutic effects simultaneously. Zhang et al. [14] constructed modified
ZIF-8 system (THINR) wrapped with glioma-associated macrophage membrane (GAMM). Chemokines CXCL10 and GAMM camouflaged with α4β1 integrin provided ZIF-8 NPs with GBM-tropic property. Chemotherapeutic Mitoxantrone (MIT) and siRNA that targeted endogenous immunosuppressive mediator IDO1 (siIDO1) were co-delivered in ZIF-8 system via intratumor nanogel implantation. The THINR-CXCL10-nanogel restrained relapse of GBM and prolonged overall survival (OS) in tumor-resected animal models.

**Liposomes**

Liposomes are the closed bilayer systems fabricated from self-assembly phospholipids. Depending on the numbers of bilayers as well as method of preparation, the particle size of liposomes ranges from nanometers to micrometers [69] (Fig. 4). Liposomes have attracted substantial attentions in DDS due to their prominent biocompatibility, high loading efficacy, extremely low cytotoxicity and low immunogenicity. The phospholipids are consisted of polar phosphate and hydrophobic lipid tails, which endows liposomes with the ability to encapsulate drug regardless of its physiochemical properties [70]. Drugs can be incorporated into the lipid bilayers [71], sequestered in the hydrophilic core [72] or conjugated on the surface of liposomes [73]. Despite that, the instability and rapid clearance of liposomes in circulation lead to attenuated efficiency, hence invading reticulo-endothelial system is essential for liposomes DDS.

Wei et al. [76] investigated the efficacies of functionalized liposome that loaded with DOX. They synthesized stable peptide DCDX and c(RGDyK) against enzymatic microenvironments through cyclization, partial D-amino acid substitution and retro-inverso isomerization while the GBM-targeting and BBB penetration function remained. Polyethylene glycol (PEG) moiety was adopted as sheath, contributing to the camouflage and prolonged circulation. Butylidenephthalide (BP) was considered to be a promising anti-GBM compound while limited by its hydrophobicity and low bioavailability [77]. Thus, Lin et al. [78] prepared BP-embraced LP@cyclodextrin (a truncated cone shape drug delivery system) complex for expanded loading efficacy and controlled release. In order to evade BBB, the liposomal formulations were administrated through intranasal path. Taken together, the uniqueness of liposomes structure that allows intercalating all kinds of therapeutic molecules highlighted their use in drug delivery.

Apart from liposomes, analogous nanoparticles such as extracellular vesicles (EV), niosomes, solid lipid nanoparticles (SLP), exosomes and microparticles were also acknowledged to be promising vehicles for drug delivery. See in Table 2.

**Inorganic Nanoparticles**

**Mesoporous Silica**

Based on the porous structure and well biocompatibility, mesoporous silica nanoparticles (MSNs) are widely applied in biomedicine and drug delivery field. According to International Union of Pure and Applied Chemistry (IUPAC), MSNs are considered to be the ordered silicon oxide structures with pore size ranging from 2 to 50 nm. MSNs possess satisfactory cell bioavailability and show inappreciable cytotoxicity in low dose (< 50 μg/mL).
The synthesis of MSNs is mainly based on silica precursors and surfactants in a template-directed method, which play an indispensable role in determining the pore size and orientation of MSNs products [86, 87]. In order to obtain GBM-tropistic function, modifications including homing ligand and magnetic molecules were introduced to MSNs. Various magnetic-MSNs were designed and the most common magnetic MSNs were composed of metal core and silica shell in an embedded core–shell manner [88, 89]. Apart from that, sandwich-structured [90], hollow-type [91] and rattle-type [92] magnetic MSNs were developed for multidisciplinary applications [93] while seldom were employed in drug delivery.

Zhu et al. [94] developed angiopep-2 modified and lipid coated mesoporous silica (ANG@LP@MSN) to delivery paclitaxel (PTX). The ang-2 and lipid layer contributed to the brain penetrating capacity and effective surface functionalization respectively. In general, MSNs exhibited burst drug release while lipid coating decreased the trend from 46 to 25% in initial 2 h. The $T_{1/2}$ (half life time) and $AUC_{blood}$ (Area under curve of the blood concentration) were increased to 4.5 and 2.5 times...
| Drug         | Composite                     | Modification                                                                 | Detail                                                                 | Result                                                                 |
|-------------|-------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------|
| Doxorubicin | DOX@CB5005@LP                 | Peptide CB5005 was employed as the cell-penetrating peptide and NF-κB inhibitor | U87 tumor spheroids were prepared to evaluate penetrating ability     | Augmented cellular uptake, increased tumor spheroid penetration and cytotoxicity |
|             |                               |                                                                              | Cell viability was determined by MTT assay                          | Enhanced BBB transport and tumor accumulating                           |
|             |                               |                                                                              | Xenograft-bearing nude mice (subcutaneous and intracranial models) were utilized to evaluate the anti-tumor efficacy | Prolonged OS                                                          |
| Paclitaxel  | Rg3@PTX@LP                    | Rg3 was a substitute of cholesterol as the building block for drug delivery liposomes. RG3 assisted membrane penetration and possessed synergistic effect with loaded anti-cancer drugs | The cellular uptake and cytotoxicity of liposomes was assessed in C6 cells | Improved glioma targeting by Rg3-glucose transporter interaction        |
|             |                               |                                                                              | Tumor spheroids and Transwell model were prepared in vitro to evaluate the penetration ability of liposome system | Enhanced BBB transport and PTX cellular uptake                         |
|             |                               |                                                                              | The TAM-modulatory effect of PTX was assessed                        | The reverse of immuno-suppressive glioma microenvironment             |
| Rapamycin   | RPM@MTI-31@DVAP@LP             | DVAP was applied as tumor homing peptide                                      | The cellular uptake and cytotoxic activity of liposome MTI-31 were evaluated in U87 cells in vitro | Increased cellular uptake and anti-proliferative effect against tumor cells |
|             |                               |                                                                              | Xenograft-bearing nude mice (intracranial models) were utilized to evaluate the anti-tumor efficacy | High selectivity and glioma targeting property                         |
|             |                               |                                                                              | Increased glioma targeting by Rg3-glucose transporter interaction | Improved median survival time                                           |
| Docetaxel   | DTX@RI7217@Muscone@LP          | RI7217 had high affinity and selectivity for TFR                            | Cell viability was determined by MTT assay                            | Enhanced BBB transport and tumor penetration                           |
|             |                               | Muscone was a musk ingredient that inhibited the expression of P-gp and MMP-9 | U87 tumor spheroids and Transwell model were prepared to evaluate penetrating ability | Improved targeting ability and anti-glioma effect in vitro and in vivo   |
| Doxorubicin | DOX@P1NS@TNC@SPIONs@LP         | P1NS was GBM-specific cell-penetrating peptide. The anti-GBM antibody TNC and superparamagnetic iron oxide provided targeted delivery property | MTS assays were used to assess cytotoxicity of BBB model was established to study liposome permeability | Enhanced BBB penetration Specific tumor tissue targeting Controlled release of encapsulated drugs Increased anti-tumor efficacy and high bio-tolerance |
| Paclitaxel  | PTX@Ang-2@A15@surviving siRNA@LP | Angiopep-2 could specifically target LPR on BBB surface. A15 was a RNA aptamer that binds to CD133 | CCK8 assay and Annexin V-FITC apoptosis assay were used to evaluate the anti-proliferative activity | Induced apoptosis of tumor marginal and internal cells Enhanced BBB transport Synergetic chemo-gene therapeutic effect Inhibition of survivin enhanced PTX activity |
respectively comparing with MSNs without lipid layer. The MSN system exerted anti-tumor efficacy (proliferation and migration) both in vitro and in vivo, inducing the cell cycle arrest of GBM cells. Nanoplatform Fe₃O₄@mSiO₂(DOX)@HSA(Ce6) was constructed by Tang et al. [95]. Due to the employment of metal molecule, magnetic guidance ability was achieved by Fe₃O₄ core surrounded with silica shell (mSiO₂). Consequently, aggregation and retention of the whole delivery system in GBM site were observed during magnetic triggering, exhibiting targeting capacity and long-lasting superiority of magnetic nanoparticles. In addition, the combination of photodynamic therapy and chemotherapy (by chlorin e6 and DOX) displayed synergistic antitumor efficacy against GBM. Additional mesoporous silica nanoparticles for GBM therapy were listed in Table 3.

Gold Nanoparticles (GNPs)
Gold nanoparticles, also recognized as AuNPs or colloidal gold, have attracted tremendous attentions on the diagnosis and drug delivery applications of GBM. GNPs have been recommended for antimicrobial applications and showed low toxicity to [102]. Synthetic GNPs have distinctive conformations such as spherical [103], cylindrical [104], cage-like [105] and hollow [106] shapes with core sizes ranging from 1 to 150 nm [107] (Fig. 5). Tunable conformations and sizes endow GNPs with unique optical and electrical properties. Surface plasmon resonance (SPR) is the optical phenomenon when GNPs form dipole oscillation in response of incoming light [108]. It has been explored in local induction heating, imaging, biosensor analysis and drug release [107]. The synthesis of GNPs is mainly based on colloidal synthesis method, in which the metal precursor, reductant and stabilizer were applied sequentially [109]. It was elaborated that the size of GNPs profoundly affected the bio-distribution in circulation. Investigation [110] revealed that GNPs with different sizes (10, 50, 100, 250 nm) exhibited distinct distribution patterns after intravenous administration. The depositions of gold were detected through inductively coupled plasma mass spectrometry (ICP-MS) and only the 10 nm GNPs were found accumulated in organs such as testis, thymus, heart and brain. The functionalizations on GNPs including peptides, antibodies and drugs, which are feasible due to the negative charge on surface [111].

Researchers [115] investigated the efficacies of functionalized GNPs that were co-loaded with DOX and HCQ (hydroxychloroquine). Programmed death 1 (PD-1) is a critical immunosuppressive receptor located on T cells, and the overexpression of which indicates the T cell depletions and immune escape in various diseases including GBM. Evidence [116] suggested that impeding PD-1/PD-L1 pathway contributed to the potential antitumor immunity. PD-L1 antibody was associated with GNP drug delivery system [115], which was consisted of peptide (Ala-Ala-Asn-Cys-Lys) conjugated polyethylene glycol-thiol (PEG-SH) and 2-cyano-6-amino-benzothiazole (CABT) conjugated PEG-SH. The modifications of peptide and CABT on GNPs significantly reduced the protein corona effects caused by intravenous administration. The stable physicochemical properties of GNPs contributed to the controlled release of DOX and HCQ in GBM local. In addition, HCQ was reported to resensitize GBM by inhibiting DOX-induced autophagy, which exerted excellent anti-GBM capacity in combine with PD-1/PD-L1 pathway blocking. Gallic acid (3,4,5-trihydroxybenzoic acid, GA) is a well-established antioxidant that shows potential anti-tumor capacity against GBM in vitro, however, the limited delivery method and poor drug availability restrict its further application. Through physical agitation adsorption, Zhou et al. [117] constructed the GA@GNPs characterized with an average diameter of 23±0.34 nm. The GA@GNPs system exhibited cytotoxic effect on GBM cells and sensitized the radiation-mediated S and G2/M cell cycle arrest.

Inorganic nanoparticles such as calcium phosphate nanoparticles (CPNs) [118], layered double hydroxides (LDHs) [119] and halloysite clay nanotubes (HNTs) [120] showed therapeutic benefits in pre-clinical GBM settings. In addition, other metal nanoparticles were designed for GBM therapy such as sliver nanoparticles (AgNPs, especially for enhancing radiosensitivity), copper oxide nanoparticles (CuONPs), zinc oxide nanoparticles (ZnONPs), iron oxide nanoparticles (IONPs), gadolinium-based nanoparticles (GdNPs, for enhancing radiosensitization) and manganese oxide nanoparticles (MnO₂NPs). The metal NPs based drug delivery systems were listed in Table 4.

Polymeric Micelles (PMs)
Polymeric micelles are the sphere-like colloidal particles consistently ranging from 10 to 100 nm [126]. PMs are composed of self-assembly copolymers, which typically possess the analogous conformations similar to phospholipids and surfactants: a hydrophilic domain and a hydrophobic domain. Apart from the most common amphiphilic copolymers (di-block) micelles, PMs that consist of tri-block copolymers (hydrophilic-hydrophobic-hydrophilic) [127, 128] and graft copolymers [129, 130] were developed for the availability of additional functionalization. Comparing to other types of DDS, PMs could act as solubilizing agents for the replacement of toxic solvents [131]. PMs with different morphologies (spherical [132], cylindrical [133], lamellar [134]) garner distinctive biological and pharmacokinetic properties,
| Drug             | Composite (TQ) | Modification | Detail                                                                                     | Result                                                                 |
|------------------|----------------|--------------|--------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Thymoquinone (TQ) [96] | TQ@CS/WA@MSN  | Chitosan and stearic acid (CS) shell could associate with GBM cell. Whey protein and gum Arabic (WA) shell promoted the internalization of the drug. | MTT assay was conducted for in vitro cytotoxicity assessment. Apoptosis and cell cycle analysis were detected through Annexin V-FITC flow cytometry. Caspase-3 activity and cytochrome-c quantitative analysis were performed. | Controlled release of TQ in acid condition. Selective cytotoxicity against GBM cells. Caspase-3 activation and G2/M arrest in tumor cells. |
| Temozolomide (TMZ) [97] | TMZ@PDA@NGR@MSN | Polydopamine (PDA) and peptide Asn-Gly-Arg (NGR) were designed to target GBM cells. | CCK8 assay and Annexin V-FITC apoptosis assay were used to evaluate the anti-proliferative activity in C6 cells. The cellular uptake was examined by inverted fluorescence microscope. | Enhanced cellular uptake of NPs system. Selective cytotoxicity against GBM cells. Induced autophagy and apoptosis in C6 cells. |
| Doxorubicin [98]   | DOX@CREKA@MSN  | Fibronectin-targeting peptide CREKA enhanced selectivity. | Vibration caused by external low-power radiofrequency (RF) field induced the drug release from MNS nanoparticles. Orthotopic athymic nude mice were utilized to assess anti-GBM efficacy. | Enhanced nanoparticle deposition in brain tumor. Satisfactory anti-GBM efficacy in vivo. |
| Temozolomide [99]  | TMZ@R8-PNA@MSN | R8 peptide nucleic acid-octaarginine could inhibit miR221. | Cell viability assay and apoptosis analysis were conducted. FACs and fluorescence confocal microscopy were utilized to assess cellular uptake. | Enhanced cellular uptake and anti-miR211 activity. Increased apoptosis of T98 cells in vitro. |
| BSeC [100]         | BSeC@cRGD@MSN  | αvβ3-targeting cRGD peptide could interact with the endothelial cells on BBB and GBM cells. | MTT assay was used to detect cell viability. Cell cycle distribution was assessed by flow cytometry. U87 spheroids and SD mice were utilized to evaluate the inhibitory effect. | Enhanced BBB and spheroids penetration. Selective cellular uptake and anti-tumor activity in vitro/vivo. Activation of p53, AKT, MAPKs pathways. |
| Arsenic trioxide (ATO) [101] | ATO@ANG@PAA@MSN | Angiopep-2 could specifically target LPR on BBB surface. Polyacrylic acid (PAA) was grafted for pH-sensitive release and supporting the lipid membrane. | Cellular uptake and intracellular disposition were measured by flow cytometry and LSM. MTI assay was used to evaluate cytotoxicity. HBMEC cells were seeded to assess BBB penetration. In vivo bio-distribution and anti-tumor study were conducted in SD mice models. | pH-responsive and sustained release of ATO. Increased BBB transport, enhanced cytotoxicity and inhibition of G2-M transition. Satisfactory in vivo bio-distribution and anti-tumor efficacy. |
among which the spherical assembly micelles were extensively elaborated (Fig. 6).

The inward-facing hydrophobic segments of copolymers serve as core in spherical PMs. In order to associate with the interior drugs, hydrophobic segments that possess various functional groups are commonly constructed by polyesters such as PLA [137], PGA [138] and PCL [139]. In addition, the camouflage outer layers of PMs play a pivotal role in stability and targeting. Numerous evidences [140, 141] have indicated the particular functions of polyethylene glycol (PEG) on drug sustained release and surface modification. The external

### Fig. 5
The TEM images of gold nanoparticles with cage-like (a), cylindrical (b), triangular (c) and hexagonal (d) morphologies. Referred from [112–114] with permission

| Drug                  | Composite                        | Modification                      | Detail                                                                 | Result                                                                 |
|-----------------------|----------------------------------|-----------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
| Verapamil (VRP) [121] | VRP@BSA@AS1411@AgNP              | Aptamer AS1411 could specifically bind to nucleolin on GBM cells and inhibit P-glycoprotein (P-gp) efflux activity | The cytotoxicity was evaluated by MTT assay in U251 cells and tumor-bearing nude mice model were employed to examine the radiosensitizing potential | Increased accumulation and cytotoxicity in vitro/vivo Decreased TrxR activity |
| Cisplatin (Pt) [122]  | Pt@si-GPX4@FA@IONP               | Folate acid was applied as tumor targeting ligand | Cell viability and proliferation were assessed using the CCK-8 assay Lipid peroxidation levels were detected by MDA assay Superoxide anion levels were detected using DHE assay | Increased apoptosis and ferroptosis in U87MG cells Selective uptake of IONP Outstanding therapeutic effect in nude mice models |
| Temozolomide [123]    | TMZ@miR-100@anti-mir-21@PEG-T7@GION | GBM cell-targeting T7 peptide was coated on GION shell | Cellular uptake was estimated by fluorescence microscope and flow cytometry Cell viability and apoptosis were assessed by PI and TUNEL staining The GION system was administered through intranasal method in nude mice model | Sensitized GBM cell to TMZ therapy Upregulated p53, PTEN, PDCD4 and Caspase-3 levels Satisfactory therapeutic outcome in vitro/vivo |
| HAPtS [124]           | HAPtS@CPTES@SPION                | HAPtS was a synthetic derivative of Trans-resveratrol, acting as antioxidant | Oxygen radical absorbance capacity (ORAC) assay was conducted as antioxidant test Clonogenic survival, FDA and MTT assay were utilized to assess cytotoxicity | Enhanced cytotoxicity against C6 cells in vitro Damage on plasma membrane instead of mitochondrial metabolism |
| Paclitaxel [125]      | PTX@LinTT1@IONW                 | Tumor homing peptide LinTT1 peptide was a recently identified ligand of p32 | Cellular uptake was evaluated by flow cytometry The in vivo bio-distribution and therapeutic effect were assessed in nude mice model | Accumulation of IONW systems in tumor site Inhibited tumor growth in vivo |
modification of biomaterials with PEG could reduce the immunogenicity of NPs, provide grafting sites and improve the surface absorption.

The micellization of amphiphilic copolymers in aqueous media is mainly dependent on hydrophobic interactions (attractive force) and occurs automatically when concentration reaches the critical micelle concentration (CMC). The CMC of each individual PMs (ranging from $10^{-7}$ to $10^{-6}$ M) is mainly affected by environmental temperature, copolymer structure and relative molecular weight [142]. Copolymers start to disassociate when concentration remains below CMC, which results in off-target effects and rapid clearance of formulation by circulation. Dispersity (D) or polydispersity index (PDI), is measured as a crucial parameter for micellization performance assessment. Evidence [73] suggested that copolymers with low dispersity (D < 1.2) were suitable for controlled drug delivery system. Therefore, determining CMC and PDI are indispensable for the development and application of PMs.

Owing to the minimal size and unique micellar structure, PMs delivery system plays an essential role in smart releasing and local accumulation comparing to conventional drug administration method. Typically, water-insoluble drugs were encapsulated in PMs to gain augmented loading capacity. It was acknowledged that cyclic peptide Arg-Gly-Asp (cRGD) could specifically bind to the αvβ3 and αvβ5 integrins overexpressed on GBM cells. The cRGD installed epirubicin (EPI)-loaded polymeric (Acetal-PEG-b-PBLA) micelles were constructed by Quader et al. [143] for GBM treatment. Specifically, the hydrazide functional groups were involved in copolymers and the constituent hydrazine-bond would contribute to the pH-sensitive property. siRNA has been recognized as promising therapeutic agent to induce target gene silencing, however, it was limited by instability and low bioavailability in vivo. Peng et al. [144] focused on the cationic polymers Poly(ethyleneimine) (PEI) which was reported to facilitate lysosomal escape of siRNA through proton sponge effect [145]. Tri-block polymeric micelle TMZ-FaPEC (Fa-PEG-PEI-PCL)@siRNA were designed to silence antiapoptotic BCL-2 gene, in which the folic acid (FA) moiety could specifically bind to the folate receptors on GBM cells. Consequently, the intracranial injection of micelle DDS exhibited significant GBM inhibition and survival benefit. The additional polymeric micelles for GBM therapeutic drug delivery employments were listed in Table 5.

**Dendrimers**

Since polypropyleneimine (PPI) and polyamidoamine (PAMAM) were firstly developed by Buhleier [150] and Donald [151] respectively, the synthetic dendrimers have emerged as profound drug delivery vehicles for their varied applicability. Dendrimers are well known for the dendritic architecture consisting of internal core and repeated external branching units [152]. The layers of repeated polymers are also recognized as generations (G) [153]. It was reported that the increase of one generation led to practically double molecular mass of dendrimers [154]. In general, the toxicity of dendrimers depends on generations, surface group and terminal moieties [155]. Introducing chemical modifications could decrease the cytotoxicity while maintaining advantageous properties [155]. The peripheral branching framework of dendrimers provides adequate graft sites for functional groups and bioactive drugs (Fig. 7), which are typically achieved by covalent conjugation, hydrogen bonding or...
Table 5  Polymeric micelle (PM) based anti-GBM drug delivery system

| Drug          | Composite                        | Modification                                                   | Detail                                                                                           | Result                                                                                      |
|---------------|----------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Camptothecin  | CPT@PEG@iRGD@IR780               | Internalizing RGD peptide possessed tumor-targeting motif CendR| Photosensitizer IR780 was loaded for combination therapy and NIR laser acted as a light-triggered switch | Controlled drug release and augmented ROS generation after laser irradiation Enhanced cellular uptake, BBB penetration and cytotoxicity Excellent anti-GBM efficacy in tumor-bearing mice |
| Paclitaxel    | PTX@L-VAP/RI-VAP@PEG-PLA          | I-VAP (SNTRVAP) is a tumor homing peptide exhibiting high binding affinity in vitro to GRP78 protein overexpressed on tumor cells | The cellular tumor spheroid, in vivo uptake of PM nanoparticle were detected Cytotoxicity was determined by MTT assay | Targeting ability for BBTB and U87 MG Greatly enhanced drug delivery efficiency and cytotoxicity Augmented in vivo anti-tumor efficacy |
| Paclitaxel    | PTX@TfR-T12@PEG-PLA              | TfR-T12 peptide could mediate the drug system to cross the BBB and specifically recognize tumor cells | Flow cytometry and CLSM were utilized to assess cellular uptake (DiR) Cytotoxicity, apoptosis, migration/invasion assay were conducted in U87MG cells Subcutaneous and orthotopic nude mice tumor model was constructed | Enhanced cellular uptake, apoptosis and endocytosis across BBTB Inhibited proliferation, migration and invasion Suppressed tumor growth in vivo |
| Temozolomide  | TMZ@siPLK@ANG2@PEC               | Ang2-modified polymers could penetrate the BBB through receptor-mediated transport and accumulate in the brain in large quantities | Flow cytometry and CLSM were utilized to assess cellular uptake (FAM-siRNA) Cell cycle and apoptosis assay were performed through flow cytometry MTT assay was conducted in LN-299, T98G and U87 In vivo anti-tumor efficacy and organ safety was evaluated in nude mice | Enhanced cellular uptake, cytotoxicity and apoptosis in tumor cells G2/M arrest caused by siPLK Enhanced TMZ sensitivity in U87RT No systemic toxicity in tumor-bearing mice |
| Curcumin (CUR)| CUR@miR21ASO@DP                  | Deoxycholic acid-conjugated polyethyleneimine (DP) was synthesized with deoxycholic acid (DA) and low-molecular weight polyethyleneimine | MTT assay, Annexin V/PI assay, and TUNEL assay were performed to evaluate anti-tumor effect in vitro Sprague Dawley rats were used to establish xenograft intracranial glioblastoma model | Induction of PDCD4 and PTEN by intratumorally injected NPs Satisfactory anti-tumor effect in vitro and in vivo |
electrostatic adsorption [156]. Additionally, segmented cavities between polymer blocks allow drug entrapment. Dendrimers can be synthesized through divergent and convergent methods, in which the conformations are constructed in the procedures of core-to-shell and shell-to-core manners respectively [157]. Depending on various compositions and generations, dendrimers and the derivatives possess engineerable sizes ranging from 1 to 15 nm [156]. In recent years, a variety of dendrimers are developed for drug delivery, including PAMAM [158], PPI [159], PLL (Poly-l-lysine) [160], PHH (phosphorus) [161], carbosilane [162] and janus [163] dendrimers. The small sizes and flexible surface modifications provide practicable BBB penetrating and GBM targeting ability for dendrimers.

Tumor-associated macrophages (TAMs) were recognized as an oncogenic factor in GBM. It was demonstrated that the infiltrating and resident macrophages/microglia could be reprogrammed by GBM cells, and the numbers of which were positively correlated with GBM grades [165]. Sharma et al. [166] focused on TAMs and designed PAMAM-OH dendrimer-based rapamycin (Rapa) conjugate. The PAMAM dendrimers with four generations were developed based on ethylenediamine core. Rapa is considered to be a promising anti-GBM reagent towards mTOR pathway and the inhibition of mTOR pathway in TAMs can induce GBM regression. Since Rapa possesses low bioavailability and extremely low aqueous solubility, PAMAM vehicle provided alternative delivery approach across BBB for Rapa administration. The DDS exhibited profound anti-tumor effects by targeting TAMs and GBM cells in vivo. Zhao et al. [167] modified PAMAM with peptide CREKA, which is characterized as tumor-homing ligand towards peritumoral fibrin deposition [168]. The G5 PAMAM was prepared with PEG-CREKA and the average of nanoparticles size was 7.52 ± 0.35 nm. In vivo imaging spectrum (IVIS) results revealed that PAMAM-PEG-CREKA had enhanced retention effect in GBM area, therefore CREKA coated PAMAM was expected to be a potential delivery system for GBM treatment. The additional researches for GBM dendrimers DDS were listed in Table 6.

**Nanogel**

As an emerging class of synthetic and multifunctional polymers, nanogel have garnered immense attentions in tissue engineering and pharmaceutical fields. Nanogel represents the combination of “hydrogel” and “nanoparticles”. It is composed by cross-linked hydrophilic polymers networks and characterized as tunable sizes (50–500 nm) and admirable elasticity [174] (Fig. 8). The construction of nanogel is based on physical crosslinks (van der Waals, electrostatic interactions and hydrogen bonding) and/or chemical covalent bonds, endowing nanogel with the conformational changeability property against environmental stimuli [175]. Nanogel particles can be synthesized in an initiated [176] or self-assembly [177] manner, through which initiator/gelator is required or not respectively. Unlike micelle, the amphiphilic associations between nanogel polymers exhibited superior stability, which is attributed to the plentiful cross-link points in nanogel instead of di-/tri-blocks structure in micelles. Numerous hydrophilic groups (such as -OH, -COOH, -CONH2 and -SO3H) and porous cavity were possessed by nanogel [178], which contributed to the swelling (water absorption) instead of dissolution of the polymeric conformation in aqueous condition. The imperative consideration on toxicity is of significance for nanogel. Consequently, natural polymers such as alginate [179], amylopectin [180], hyaluronic acid [181] and chitosan [182] have been utilized as building blocks for nanogel drug delivery system.

The release of encapsulated drugs is mainly based on passive diffusion. The swelling of nanogel enlarges the interior mesh size and allows the entrapped drugs release. Therefore, micro-molecules are prone to release in a burst manner while macro-molecules (protein, peptides) in nanogel exhibit sustained release [174]. Additionally, the degradation of physical/chemical bonds between polymeric chains results in hydrolysis of whole delivery system and drug release. In this regard, factors that can trigger the swelling or degradation of polymeric networks enable nanogel to perform stimulus–response property [183]. Environmental factors such as temperature, pH, ionic change, redox and light are exploited as stimuli for the responsive controlled drug release. As described before, the micro-environment of tumor possesses lower pH level due
| Drug            | Composite       | Modification                                                                 | Detail                                                                 | Result                                                                                           |
|-----------------|-----------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Celecoxib (CXB) | CXB@G3BC31      | Biotinylated third generation of the poly (amidoamine) dendrimer was substituted with 31 CXB residues | The cellular uptake, proliferation, migration and apoptosis were assessed in U-118 cells Model organism nematode Caenorhabditis elegans was used in toxicological studies | Cellular accumulation of dendrimer NPs in the lysosomes of tumor cells Up-regulated COX-2 level and cell cycle arrest Anti-tumor effect in vitro |
| Arsenic trioxide (ATO) | ATO@cRGD@mPEG@PAMAM | cRGD can bind to αvβ3 integrin peptides and combine with the integrin receptors on BBB | Cellular uptake, hemolytic toxicity and cytotoxicity were detected in C6 cells Intracellular disposition and BBB penetration were assessed Therapeutic efficacy was evaluated in Wistar rats model | Enhanced BBB penetration and intracellular disposition Cell cycle perturbations in G2/M phase Excellent therapeutic effect in vitro/vivo |
| TRAIL [171]    | TRAIL@Tf@PAMAM  | Transferrin (Tf) receptor were overexpressed on BBB and utilized for facilitating brain targeting | Cellular uptake and apoptosis were determined in C6 cells Tumor xenografted SD rat model was established MRI imaging was utilized to monitor therapeutic effect | Accumulated NPs in brain tumor site Induced cell apoptosis Prolonged mean survival time and decreased tumor volume |
| Rapamycin (RAPA) | RAPA@PAMAMOH    | Hydroxyl PAMAM dendrimers (PAMAMOH) had the unique ability to target activated microglia | BV2 microglia were activated with IFNγ for inflammation analysis Anti-proliferative activity in GL261 cells was detected by MTT assay Systemic toxicity and anti-tumor evaluation were completed in C57BL/6 orthotopic mice model | Ablation and repolarization of TAMs Augmented anti-proliferative and tumor specificity properties in vitro Improved therapeutic efficacy in vivo |
| Doxorubicin [173] | DOX@Borneol@ANG-2@PAMAM | Angiopep-2 could specifically target LPR on BBB surface Borneol promoted the permeation of drugs across BBB and enhanced their distribution in the brain tissue | Cellular uptake and intracellular disposition were detected through LSCM in HBMEC cells BBB penetration model was established In vitro cytotoxicity on HBMEC and C6 cells were evaluated | Sustained pH-sensitive DOX release Enhanced cytotoxicity and BBB penetration Promoted tumor specific NPs uptake level |
to excessive apoptosis and Warburg effect when comparing to blood and normal tissue (pH 7.4). The methacrylated hyaluronic acid (MAHA) nanogel [184] was designed for pH-sensitive drug release against GBM. Cross-linking gelator MA-OE-MA forms ortho ester linkages with MAHA via aqueous dispersion polymerization. The acid-labile ortho ester bond was effectively sensitive to mildly acid condition [185]. Therefore, the hydrolysis of chemical bonds between polymers and gelators lead to the release of embedded DOX, achieving anti-GBM capacity and tumor targeting. Thermos-responsive nanogel with negative sensitivity is characterized by lower critical solution temperature (LCST). At the temperature lower than LCST, the polymers form hydrogen bonds with water and exhibit in a swollen state. When the temperature reach LCST, the hydrophobic interaction between polymers dominate and the conformation of nanogel appear to shrink and collapse [183, 186]. Lu et al. [187] integrated GO into chitosan nanogel to transport irinotecan, cetuximab and SLP2 shRNA against GBM. The nanogel system exhibited thermo-sensitive characteristic with phase transition temperature/LCST at 32 °C. At room temperature, GO that loaded with drugs and shRNA were embedded into the liquid phase nanogel. The injection of chitosan nanogel into GBM area (>32 °C) enabled the dehydration and solidification of nanogel, contributing to the subsequent sustained release of anti-tumor agents in situ. The additional nanogel DDS for GBM therapeutic employments were listed in Table 7.

**Discussion**

In 1986, Matsumura [193] proposed a phenomenon where nanoparticles with specific sizes displayed tumor accumulation properties. This tumoritropic performance was then recognized as enhanced permeability and retention (EPR) effect and played an indispensable role in nanoscale drug delivery therapy field (Fig. 9). With respect to tumorous tissues, the augmented angiogenesis is prone to accompany with wide inter-endothelial gap, poor vessel structural integrity and lymphatic reflux deficiency. These vascular alterations enable micromolecular substances (100 nm to 200 nm) to selectively permeate and retain in tumor surroundings [194]. The EPR effect endows drug delivery systems with passive targeting ability and contributes to increased therapeutic efficiency as well as reduced systemic side effects. However, controversy exists since the EPR effect tremendously varies intratumorally and intertumorally due to distinct tumor microenvironments and vascular densities [195, 196]. Warrenet al. [197] demonstrated that rare nanoparticles could passively penetrate into the tumor vessels of ovarian cancer, breast cancer and GBM. Based on mouse models, human tumorous tissues and mathematical models, conclusion was made that 97% of nanoparticles were transported through active process instead of passive diffusion [197]. Ding et al. [198] held opposite opinion that 87% renal cancer exhibited significant EPR effect, despite considerable heterogeneity was also observed in tumors with different size and gender (male samples showed intensified EPR) [198]. The EPR effect
Table 7 Nanogel based anti-GBM drug delivery system

| Drug          | Composite | Modification | Detail                                                                 | Result                                                                 |
|---------------|-----------|--------------|----------------------------------------------------------------------|------------------------------------------------------------------------|
| Teriflunomide (TFM) [188] | TFM@Gellan gum@Carbopol 974P | Gellan gum and carbopol 974P were applied as gelling and mucoadhesive agents | Ex vivo nasal permeation was performed by using vertical Franz diffusion cell. Cellular uptake, bio-distribution and proliferation were evaluated in U87MG cells. Systematic toxicity and bio-distribution were determined in Swiss albino mice model. | Enhanced nasal permeation and brain accumulation through i.n. delivery. High cytotoxicity potential against tumor cells. No hepatotoxicity, nephrotoxicity and hematological toxicity. |
| Doxorubicin [189] | DOX@Lf@PBA@HA | Lactoferrin was coated onto the nanogels to achieve blood brain barrier penetration. Hyaluronic acid and phenylboronic acid provided dual targeting for tumor. Cellular uptake and disposition were determined through flow cytometry and CLMS. B.End3/G422 coculture model was used to study the transport ability. SD rats and ICR mice were utilized to investigate anti-tumor efficacy and bio-distribution respectively. | | Triggered drug release manner by high GSH. Increased celluptake through clathrin and caveolin-mediated endocytosis. Optimized bio-distribution and higher permeation ability. |
| TSPO ligand [190] | TSPO ligand-DEX@NG | Cholesterol and porphyrins are known as endogenous ligands for Translocator protein. MTT assay and fluorescence microscopy were utilized in C6 cells. Swelling study and rheological study were used to analyze the viscoelastic properties. | | Proven cellular uptake and cytotoxicity in vivo. Excellent stability and controlled release of NG system. |
| TMZ&PTX [191] | TMZ@PTX@PEG-DMA | Intratumoral implantation was used instead modifications on NG. | Clonogenic assay was conducted. Orthotopic U87MG human GBM tumor resection nude mice model was established. | Synergistic effect of PTX and TMZ on U87MG cells. Perisurgical drug delivery in the resection cavity. |
| Cisplatin [192] | CPT@Cx43 mAb@BSAT1 mAb@NG | The preferential expression of membrane protein connexin 43 (Cx43) and brain-specific anion transporter (BSAT1) in the tumor was employed for targeted drug delivery. MTS assay was used to evaluate in vitro cytotoxicity on C6 cells. Intracranial inoculation of rat glioma 101/8 was constructed. Tumor volume was determined by MRI scanning. | | Higher passive penetration across endothelial barrier. Increased drug delivery efficacy and internalization in tumor site. Prolonged survival time for animal model. |
may eventually depend on the specific tumor pathophysiology, because differences were observed in the variety of tumor types. Although numerous EPR effect studies based on animal models achieved significant efficacy, the majority of which were failed to be translated into clinic [199]. Therefore, more intensive investigations should be conducted to fully illustrate the EPR effect behind nanoparticle drug delivery platforms.

Conventional anti-GBM drug delivery is invariably accompanied by unsatisfactory bio-distribution and systemic side effects. Since plenty of therapeutic agents against GBM cells fail to reach the action site and function in vivo, novel nanoscale biomaterials have been developed as vehicle to escort them. For one thing, nanoparticle delivery systems play an indispensable role in drug camouflage. The association between therapeutic agents and biomaterials can significantly improve the stability, solubility and bioavailability of drugs, which contributes to excellent pharmacokinetic performances (increased blood-drug concentration, prolonged half-life, etc.) of nanodrugs [2]. It is widely acknowledged that the most critical obstacle on GBM medication is BBB. Hydrophobic nanoparticles (liposomes, polymeric micelles) as well as modifications (transferrin/lactoferrin conjugation) were developed to increase the permeability of BBB. For another, actively GBM-specific property can be managed by nano-biomaterials. Several ligands such as FA, oligopeptide cRGD, Ang-2 and A7R [200] were associated with NPs to enhance their selectivity. The GBM-homing characteristic plays a pivotal role in decreased drug delivery frequency and reduced off-target effects.

The novel anti-GBM therapeutic agents range from chemotherapeutic drugs to chemokine, oligonucleotide, siRNA/shRNA, protein and etc. Therefore, diverse nanoparticle systems were utilized based on their unique characteristics and the associations with drugs. Sjoerd et al. [201] developed terminally functionalized PEG-b-PS and PEG-b-PDLLA libraries with 32 variants. The different amine groups on the terminal of PEG polymers allowed the chemical conjugations with specific drugs as well as the subsequent modifications through click chemistry reactions. Additionally, based on the physical characteristics such as size, charge, magnetism, hydrophobicity and photoexcitability, varied nanoparticles are selected to transport the drugs with diverse properties.

![Fig. 9](image.png)

**Fig. 9**  
(a) Schematic representation of the conceptual passive targeting (EPR effect) of nanomedicine. 
(b) Active targeting of nanomedicine grafted with peptide or antibody able to bind specific receptors overexpressed by (1) cancer cells or (2) endothelial cells. Referred from [199] with permission
interfering RNA (siRNA) is able to inhibit the expression of specific mRNA and is employed for cancer therapy. However, the vulnerable siRNA can be easily degraded by widely-existing RNase, repelled by cell membranes with the same negatively charge [202]. Cationic nanoparticles such as dendrimers, polymers and liposomes were used to carry siRNA via electrostatically association and protect it from rapid renal/phagocytic clearance [203].

Nanoscale DDS are also applied in diagnostic imaging, hyperthermia therapy and photodynamic therapy against GBM [204, 205]. Near-infrared (NIR) dye has been used as a noninvasive, real-time, in situ fluorescence imaging tool [206]. The cooperation of photosensitizers and NPs could provide tumor targeting property [207], in which the active-targeting NIR exhibited profound potential on precise phototheranostics [9, 208]. In recent, more and more investigations focused on multimodal theranostic regimens. For example, superparamagnetic \( Fe_3O_4 \) nanoparticles was applied for magnetic fluid hyperthermia (MFH) and could be combined with chemotherapy drugs [209] as well as NIR hyperthermia [210]. Specifically, the administration routes of GBM delivery systems expanded to intravenous injection, nasal inhalation, and in situ implantation, which provided available strategies for appropriate treatment of GBM.

It was widely acknowledged that the significance of nanoscale biomaterials in drug delivery had been profoundly improved in the past few years due to their unique structures and properties. The prodigious progresses that have been made in biomedical field contributed to the diagnostic and therapeutic applications of anti-GBM nanoparticles. However, the majority of GBM nanoparticles investigations ended up at animal models and rare of these could enter preclinical stages. GBM is characterized by remarkably intra and inter-tumoral heterogeneity, therefore the inbred strain models lack complexity and diversity to reproduce human GBM. Except from BBB, biological or pathological barriers such as mononuclear phagocyte system, renal clearance, opsonization and blood tumor barrier (BTB) also have significant impacts on insufficient nanoparticles accumulation [211]. Additionally, limitations still exist on the safety issue. Although most nanoparticles exhibit excellent biocompatibility and biodegradability, fundamental investigations on the potential toxicity, immunogenicity, genotoxicity and bio-pharmacokinetics (absorption, distribution, metabolism, excretion) of each biomaterial must be scrupulously assessed in vivo. The bio-implants may trigger foreign body reactions (FBR) [212, 213], and hence the underlying influences of activated immune system on biomaterials, local homeostasis and even prognosis should be cautiously concerned. Despite the emergence of numerous nanoscale DDS for GBM treatment, explorations on effective dosage and bioavailability should also be scrupulously considered to minimize the side effects.

Currently, a great many of studies in drug delivery field still focused on pre-existing nanoparticles/biomaterials. The innovations of those DDS were mainly confined to superficial modifications and/or simply nanohybrid formation of multiple nanoparticles. Consequently, the development of novel biomaterials with superior vehicle capability is urgently needed for GBM therapy. Besides, despite most studies have described the material characterization of NPs thoroughly, investigations on the specific biological pathways behind DDS were comparatively inadequate.

In the future, more and more molecular targets behind GBM will be discovered. Therefore, the interdisciplinary nanoscale DDS that are able to precisely deliver the associated therapeutics will play a more significant role in GBM therapy.

**Conclusion**

In this review, the major types of drug delivery systems in GBM were clarified, and each of them were systematically interpreted and exemplified. The advantages and limitations of drug delivery systems were discussed, mainly covering safety, design, synthesis, bio-distribution, functionalization and efficiency. In the discussion, challenges and opportunities for GBM nanodrug therapy were proposed.

**Abbreviations**

GBM: Glioblastoma multiforme; NPs: Nanoparticles; DDS: Drug delivery system; BBB: Blood–brain-barrier; BTB: Blood tumor barrier; RME: Receptor-mediated endocytosis; AME: Absorptive-mediated endocytosis; CNTs: Carbon nanotubes; GBNs: Graphene-based nanoparticles; CQDs: Carbon quantum dots; MOFs: Metal–organic frameworks; LPs: Liposome particles; MSNs: Mesoporous silica nanoparticles; GPs: Gold nanoparticles; PMs: Polymeric micelles; EPR: Enhanced permeability and retention; NIR: Near-infrared; DOX: Doxorubicin; TMZ: Temozolomide; CPT: Camptothecin; RAPA: Rapamycin; CXB: Celecoxib; PTX: Paclitaxel; MFH: Magnetic fluid hyperthermia; CMC: Critical micelle concentration; SPR: Surface plasmon resonance.

**Acknowledgements**

We thank Qian Xia and Zixiao Wang for providing advice assistance.

**Authors’ Contributions**

XT and LQ proposed the draft. ZH and XS was the major contributor in writing the manuscript. HD and ZR made the graphic abstract and tables. All authors read and approved the final manuscript.

**Funding**

This work was supported by Natural Science Foundation of China (81471517), Key project of Shandong Provincial Natural Science Foundation (ZR202010300086), Key Research and Development Program of Shandong Province (2019GSF107046).

**Availability of Data and Materials**

Not applicable.
Declarations

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Neurosurgery, Shandong Provincial Hospital, Cheelo College of Medicine, Shandong University, Jinan 250021, China. 2 Department of Neurosurgery, Shandong Provincial Qianfoshan Hospital, Cheelo College of Medicine, Shandong University, Jinan 250014, China. 3 Department of Neurosurgery, Shandong Provincial Qianfoshan Hospital, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Medicine and Health Key Laboratory of Neurosurgery, Jinan 250014, China. 4 Department of Histology and Embryology, School of Basic Medical Sciences, Cheelo College of Medicine, Shandong University, Jinan 250012, China. 5 Department of Neurosurgery, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, Nanchang Jiangxi 330006, China.

Received: 25 November 2021 Accepted: 9 February 2022

Published online: 16 February 2022

References

1. Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP et al (2020) Globolastoma in adults: A society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22(8):1073–1113
2. Li J, Zhao J, Tan T, Liu M, Zeng Z, Zeng Y et al (2020) Nanoparticle drug delivery system for glioma and its efficacy-improvement strategies: a comprehensive review. Int J Nanomedicine 15:2563–2582
3. Partridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1):3–14
4. Liu HM, Liu XF, Yao JL, Wang CL, Yu Y, Wang R (2006) Utilization of combined chemical modifications to enhance the blood-brain barrier permeability and pharmacological activity of endomorphin-1. J Pharmaceut Exp Ther 319(1):308–316
5. Dallinger S, Lober S, Klingenstein R, Korth C, Gmeiner P (2006) A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations. J Med Chem 49(22):6591–6595
6. Lu W, Sun Q, Wan J, She Z, Jiang XG (2006) Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 66(24):11878–11887
7. Xue J, Zhao Z, Zhang L, Xue L, Shen S, Wen Y et al (2017) Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol 12(7):692–700
8. Xu HL, Yang JJ, ZhuGe DL, Lin MT, Zhu QY, Jin BH et al (2018) Glia-targeted delivery of a theranostic liposome integrated with quantum dots, superparamagnetic iron oxide, and cinglentide for dual-imaging guiding cancer surgery. Adv Healthc Mater 7(9):e1701130
9. Geng X, Gao D, Hu D, Liu Q, Gao C, Yuan Z et al (2020) Active-targeting NIR-II phototheranostics in multiple tumor models using platelet-camouflaged nanoprobes. ACS Appl Mater Interfaces 12(50):53624–53637
10. Han Y, Gao C, Wang H, Sun J, Liang M, Feng Y et al (2021) Macrophage membrane-coated nanocarriers co-modified by RGD and TIP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer’s disease mice. Bioact Mater 6(2):529–542
11. Tiwari AP, Hwang TI, Oh JM, Maharjan B, Chun S, Kim BS et al (2018) pH/NIR-responsive polypropylene-functionalized fibrous localized drug-delivery platform for synergistic cancer therapy. ACS Appl Mater Interfaces 10(24):20256–20270
12. Choy Y, Kim J, Yu S, Hong S (2020) pH- and temperature-responsive radially porous silica nanoparticles with high-capacity drug loading for controlled drug delivery. Nanotechnology 31(33):335103
13. Sun P, Huang T, Wang X, Wang G, Liu Z, Chen G et al (2020) Dynamic-covalent hydrogel with NIR-triggered drug delivery for localized chemo-photorhetero combination therapy. Biomacromol 21(2):556–565
14. Zhang J, Chen C, Li A, Jing W, Sun P, Huang X et al (2021) Immuno-stimulant hydrogel for the inhibition of malignant glioma relapse post-resection. Nat Nanotechnol 16(5):538–548
15. Luo Z, Sun W, Fang J, Lee K, Li S, Gu Z et al (2019) Biodegradable gelatin methacryloyl microspheres for transdermal drug delivery. Adv Healthc Mater 8(3):e1801054
16. Zhang Q, Zhu H, Xu F, Dai X, Shi L, Cai W et al (2019) The interleukin-4/PPARγ signaling axis promotes oligodendrocyte differentiation and remyelination after brain injury. PLoS Biol 17(6):e3000330
17. Zambrano-Andazol I, Vazquez N, Chacon M, Sanchez-Avila RM, Persinal M, Blanco C et al (2020) Reduced graphene oxide membranes in ocular regenerative medicine. Mater Sci Eng C Mater Biol Appl 114:111075
18. Henna TK, Raphay VR, Sankar R, Rameena Shirin VK, Gangadharappa HV, Pramod K (2020) Carbon nanomaterials: the drug and the delivery system for brain disorders. Int J Pharm 587:119701
19. Mehra NK, Palakurthi S (2016) Interactions between carbon nanotubes and bioactivities: a drug delivery perspective. Drug Discov Today 21(4):585–597
20. Sajid MI, Jamshaid U, Jamshaid T, Zafar N, Fessi H, Elaissari A (2016) Carbon nanotubes from synthesis to in vivo biomedical applications. Int J Pharm 501(1–2):278–299
21. Yan H, Xue Z, Xie J, Dong Y, Ma Z, Sun X et al (2019) Toxicity of carbon nanotubes as anti-tumor drug carriers. Int J Nanomedicine 14(10):10797–10914
22. Francis AP, Devasena T (2018) Toxicity of carbon nanotubes: a review. Toxicol Ind Health 34(3):200–210
23. He H, Pham-Huy LA,DRAMO P, Xiao D, Zuo P, Pham-Huy C (2013) Carbon nanotubes: applications in pharmacy and medicine. Biomed Res Int 2013:578290
24. Romano-Feinholz S, Salazar-Ramiro A, Munoz-Sandoval E, Magana-Maldonado R, Hernandez Pedro N, Rangel Lopez E et al (2017) Cytotoxicity induced by carbon nanotubes in experimental malignant glioma. Int J Nanomedicine 12:6005–6026
25. Alizadeh D, White EE, Sanchez TC, Liu S, Zhang L, Badie B et al (2018) Immunostimulatory CpG on carbon nanotubes selectively inhibits migration of brain tumor cells. Bioconjug Chem 29(5):1659–1668
26. Salazar A, Pérez-de la Cruz Y, Muñoz-Sandoval E, Chavarsa V, García Morales ML, Espinosa-Bonilla A et al (2021) Potential use of nitrogen-doped carbon nanotube sponges as payload carriers against malignant glioma. Nanomaterials (Basel) 11(5)
27. You Y, Wang N, He L, Shi C, Zhang D, Liu Y et al (2019) Designing dual-functionalized carbon nanotubes with high blood-brain-barrier permeability for precise orthotopic glioma therapy. Dalton Trans (Cambridge, England). 2003(48):S1569–1573
28. Chowdhury SM, Surhand C, Sanchez Z, Chaudhary P, Suresh Kumar MA, Lee S et al (2015) Graphene nanoribbons as a drug delivery agent for luncathone mediated therapy of glioblastoma multiforme. Nanomedicine 11(1):109–118
29. Moore TL, Grimes SW, Lewis RL, Alexis F (2014) Multilayered polymer-coated carbon nanotubes to deliver dasatinib. Mol Pharm 11(1):276–282
30. Kafa H, Wang JT, Rubio N, Klippstein R, Costa PM, Hassan HA et al (2016) Translocation of LRP1 targeted carbon nanotubes of different diameters across the blood-brain barrier in vitro and in vivo. J Control Release 225:217–229
31. Liao C, Li Y, Tjong SC (2018) Graphene nanomaterials: synthesis, bio-compatibility, and cytotoxicity. Int J Mol Sci 19(11)
32. Hoseini-Ghahfarokhi M, Mirkiani S, Mozaffari N, Abdolahi Sadatlu MA, Ghasemi A, Abbaspour S et al (2020) Applications of graphene and graphene oxide in ocular drug delivery system for brain disorders. Int J Pharm 587:119701
33. Patil TV, Patel DK, Dutta SD, Ganguly K, Lim KT (2021) Graphene oxide-based stimuli-responsive platforms for biomedical applications. Molecules 26(9)
34. XiaoYe Wang AN (2018) Klaus Müllen Precision synthesis versus bulk-scalable fabrication of graphenes. Nat Rev Chem 20100
35. Lakshmanan R, Maulik N (2018) Graphene-based drug delivery systems in tissue engineering and nanomedicine. Can J Physiol Pharmacol 96(9):869–878
36. Agraval M, Tripathi DK, Saraf S, Saraf S, Antimisiaris SG et al (2017) Recent advancements in liposomes targeting strategies to cross
37. Song MM, Xu HL, Liang JX, Xiang HH, Liu R, Shen YX (2017) Lactoferrin modified graphene oxide iron oxide nanocomposite for glioma-targeted drug delivery. Mater Sci Eng C Mater Biol Appl. 77:904–911.

38. Zhao Y, Yin H, Zhang X (2020) Modification of graphene oxide by angiopep-2 enhances anti-glioma efficiency of the nanoscaled delivery system for doxorubicin. Aging (Albany NY) 12(11):10506–10516.

39. Wang P, Wang X, Tang Q, Chen H, Zhang Q, Jiang H et al (2020) Functionalized graphene oxide against U251 glioma cells and its molecular mechanism. Mater Sci Eng C Mater Biol Appl. 116:111571.

40. Wang LH, Liu JY, Sui L, Zhao PH, Ma HD, Wei Z et al (2020) Folate-modified graphene oxide as the drug delivery system to load temozolomide. Curr Pharm Biotechnol. 21(11):1088–1098.

41. Shirvalilou S, Khoei S, Khoee S, Raoufi NJ, Karimi MR, Shakeri-Zadeh A (2018) Development of a magnetic nano-graphene oxide carrier for improved glioma-targeted drug delivery and imaging. In vitro and in vivo evaluations. Chem Biol Interact. 295:97–108.

42. Wei Y, Zhou F, Zhang D, Chen Q, Xing D (2016) A graphene oxide based smart drug delivery system for tumor mitochondria-targeting photodynamic therapy. Nanoscale 8(6):3530–3538.

43. Tian XT, Yin XB (2019) Carbon dots, unconventional preparation strategies, and applications beyond photoluminescence. Small 15(184):e1900383.

44. Pardo J, Peng Z, Leblanc RM (2018) Cancer targeting and drug delivery using carbon-based quantum dots and nanotubes. Molecules 23(2).

45. Kang Z, Lee ST (2019) Carbon dots: advances in nanocarbon applications. Nanoscale 11(41):19214–19224.

46. Shen JM, Gao FY, Yin T, Zhang HX, Ma M, Yang YJ et al (2013) cRGD-functionalized polymeric magnetic nanoparticles as a dual-drug delivery system for safe targeted cancer therapy. Pharmacol Res. 70(1):102–115.

47. Song B, Wu C, Chang J (2012) Dual drug release from electrosyn polylactic-co-glycolic acid/mesoporous silica nanoparticles composite mats with distinct release profiles. Acta Biomater. 8(5):1901–1907.

48. Hettiarachchi SD, Graham RM, Mintz KJ, Zhou Y, Vanni S, Peng Z et al (2019) Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors. Nanoscale 11(13):6192–6205.

49. Wang S, Li C, Qian M, Jiang H, Shi W, Chen J et al (2017) Augmented glioma-targeted theranostics using multifunctional polymer-coated carbon nanodots. Biomaterials 141:29–39.

50. Mura S, Nicolas J, Couvreur P (2013) Stimuli-responsive nanocarriers for improved glioma-targeted drug delivery and imaging: In vitro and in vivo evaluations. Chem Biol Interact. 295:97–108.

51. Almeida B, Nage OK, Rogers KE, Delechanty JB (2020) Recent progress in bioconjugation strategies for liposome-mediated drug delivery. Molecules 25(23).

52. Chen J, Lu WL, Gu W, Lu SS, Chen ZP, Cai BC et al (2014) Drug-in-cyclodextrin-in-liposomes: a promising delivery system for hydrophobic drugs. Expert Opin Drug Deliv 11(4):565–577.

53. Ahmed S, Convis Y, Gahoual R, Euan A, Lai-Kuen R, Couillaud BM et al (2019) Conception of nanoized hybrid liposome/poloxamer particles to thicken the interior core of liposomes and delay hydrophilic drug delivery. Int J Pharm 748:7683–7689.

54. Lin PC, Lin SZ, Chen YL, Chang JS, Ho LI, Liu PY et al (2011) Butylide-2-naphthalide suppresses human telomerase reverse transcriptase (TERT) in human glioblastomas. Ann Surg Oncol 18(12):3514–3527.

55. Lengyel JS, Milne JL, Subramaniam S (2008) Electron tomography in nanoparticle imaging and analysis. Nanomedicine (Lond) 3(1):125–131.

56. Wei X, Gao J, Zhan C, Xie C, Chai Z, Ran D et al (2015) Liposome-based glioma targeted drug delivery enabled by stable peptide ligands. J Control Release 218:13–21.

57. Lin PC, Lin SZ, Chen YL, Chang JS, Ho LI, Liu PY et al (2011) Butylnaphthalide suppresses human telomerase reverse transcriptase (TERT) in human glioblastomas. Ann Surg Oncol 18(12):3514–3527.

58. Lin LY, Chen YS, Li YS, Chen SR, Lee CH, Huang MH et al (2020) Liposome consolidated with cyclodextrin provides prolonged drug retention resulting in increased drug bioavailability in brain. Int J Mol Sci 21(12).

59. Zhang Y, Zhang L, Hu Y, Jiang K, Li Z, Lin YZ et al (2019) Cell-penetrable NF-kappaB inhibitor-conjugated liposomes for treatment of glioma. J Control Release 289:102–113.

60. Zhu Y, Liang J, Gao C, Wang A, Xia J, Hong C et al (2021) Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy. J Control Release 330:641–657.
81. Wang X, Meng N, Wang S, Zhang Y, Lu L, Wang R et al (2019) Non-immunogenic, low-toxicity and effective glioma targeting MTF-31 liposomes. J Control Release 316:381–392
82. Kang S, Duan W, Zhang S, Chen D, Feng J, Qi N (2020) Muscone/R7217 co-modified upward messenger DTX liposomes: enhanced permeability of blood-brain barrier and targeting glioma. Theranostics 10(10):4308–4322
83. Shi D, Mi G, Shen Y, Webster TJ (2019) Glioma-targeted dual functionalized thermosensitive Ferri-liposomes for drug delivery through an in vitro blood-brain barrier. Nanoscale 11(32):15057–15071
84. Sun X, Chen Y, Zhao H, Gao Q, Liu M, Zhang C et al (2018) Dual-modified cationic liposomes loaded with pacitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma. Drug Deliv 25(1):178–1727
85. Li Z, Zhang Y, Feng N (2019) Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery. Expert Opin Drug Deliv 16(3):219–237
86. Wang Y, Zhao Q, Han N, Bai L, Li J, Liu J et al (2015) Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine 11(2):313–327
87. Tang F, Li L, Chen D (2012) Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 24(12):1504–1534
88. Zhang T, Huang B, Elzatary AH, Alghamdi A, Yue Q, Deng Y (2020) Synthesis of porphyrin magnetic mesoporous silica nanochains for use as enzyme support and nanostirrer in biocatalysis. ACS Appl Mater Interfaces 12(15):19701–19708
89. Shi M, Zhang J, Li J, Fan Y, Wang J, Sun W et al (2019) Polydopamine-coated magnetic mesoporous silica nanoparticles for multimodal cancer theranostics. J Mater Chem B 7(10):366–372
90. Zhao W, Gu L, Zhang L, Chen H, Shi J (2005) Fabrication of uniform magnetic monocomposite spheres with a magnetic core/mesoporous silica shell structure. J Am Chem Soc 127(25):8916–8917
91. Chen Y, Chen H, Guo L, He Q, Chen F, Zhou J et al (2010) Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy. ACS Nano 4(1):529–539
92. Ding S, Chen JS, Qi G, Duan X, Wang Z, Giannelis EP et al (2011) Formation of SnO2 hollow nanospheres inside mesoporous silica nanoresorbers. J Am Chem Soc 133(1):2123
93. Zuo B, Li W, Wu X, Wang S, Deng Q, Huang M (2020) Recent advances in the synthesis, surface modifications and applications of core-shell magnetic mesoporous silica nanospheres. Chem Asian J 15(8):1248–1265
94. Zhu J, Zhang Y, Chen X, Zhang Y, Zhang K, Zheng H et al (2021) Angioperoxidase-2-modified lipid-coated mesoporous silica nanoparticles for glioma targeting therapy overcoming BBB. Biochim Biophys Acta Mol Com 534:902–907
95. Tang XL, Jing F, Liu B, Cui S, Yu RT, Shen XD et al (2018) pH-responsive magnetic mesoporous silica-based nanoplatform for synergetic photodynamic therapy/chemotherapy. ACS Appl Mater Interfaces 10(17):15001–15011
96. Shaheen SA, Aboul-Enein EM, Higazy IM, Abou-Elella F, Lijovskij W, Ahmed ER et al (2019) Targeted anticancer potential against glioma cells of thymoquinone delivered by mesoporous silica core-shell nanoformulations with pH-dependent release. Int J Nanomed 14:5503–5526
97. Zhang P, Tang M, Huang Q, Zhao G, Huang N, Zhang X et al (2019) Combination of 3-methyladenine therapy and Asn-Gly-Arg (NGR)-modified mesoporous silica nanoparticles loaded with temozolomide for glioma therapy in vitro. Biochim Biophys Acta Commun 534:902–907
98. Turan O, Bielecki P, Perera V, Lorkovski M, Covarriubias G, Tong K et al (2019) Delivery of drugs into brain tumors using multicomponent silica nanoparticles. Nanoscale 11(24):11910–11921
99. Bertucci A, Prayestiano EA, Sephiardi D, Manicardi A, Brognera E, Gambare R et al (2015) Combined delivery of temozolomide and anti-miR-217 PNA using mesoporous silica nanoparticles induces apoptosis in resistant glioma cells. Small 11(42):5687–5695
100. You Y, Yang L, He L, Chen T (2016) Tailored mesoporous silica nanosystem with enhanced permeability of the blood-brain barrier to antagonize glioblastoma. J Mater Chem B 4(36):5980–5990
101. Tao J, Fei WW, Tang H, Li J, Mu C, Zhang Y et al (2019) Angioperoxidase-2-conjugated “core-shell” hybrid nanovehicles for targeted and pH-triggered delivery of arsenic trioxide into glioma. Mol Pharm 16(2):785–797
102. Boisselier E, Astruc D (2009) Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 38(6):1759–1782
103. Lee YJ, Cha SH, Kim H, Choi SE, Cha S, Park Y (2020) Diallyl disulphide–loaded spherical gold nanoparticles and acorn-like silver nanoparticles synthesised using onion extract: catalytic activity and cytotoxicity. Artif Cells Nanomed Biotechnol 48(1):948–960
104. Kim DS, Kang ES, Baek S, Choo SS, Chung YH, Lee D et al (2018) Electrochemical detection of dopamine using periodic cylindrical gold nanoelectrode arrays. Sci Rep 8(1):14049
105. Mondal B, Mukherjee PS (2018) Cage encapsulated gold nanoparticles as heterogeneous photocatalyst for facile and selective reduction of nitroarenes to aze compounds. J Am Chem Soc 140(39):12592–12601
106. Imanparast A, Bakhshizadeh M, Salek R, Sazgami A (2018) Pegylated hollow gold-mitoaxonante nanoparticles combining photodynamic therapy and chemotherapy of cancer cells. Photodiagnosis Photodyn Ther 23:295–305
107. Singh P, Pandit S, Mokkapati V, Gang A, Ravikumar V, Mijakovic I (2018) Gold nanoparticles in diagnostics and therapeutics for human cancer. Int J Mol Sci 19(7)
108. Capek I (2017) Polymer decorated gold nanoparticles in nanomedicine conjugates. Adv Colloid Interface Sci 249:386–399
109. Austin LA, Mackey MA, Dreden EC, El-Sayed MA (2014) The optical, photothermal, and surface chemical properties of gold and silver nanoparticles in biodiagnostics, therapy, and drug delivery. Arch Toxicol 88(7):1391–1417
110. De Jong WH, Hagens WJ, Krystek P, Burger MC, Sips AJ, Geertsma RE (2008) Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 29(12):1912–1919
111. Mousavi SM, Zarei M, Hashemi SA, Ramakrishna S, Chiang WH, Lai CW et al (2020) Gold nanostars-diagnosis, biomaging and biomedical applications. Drug Metab Rev 52(2):299–318
112. Lee C, Hwang HS, Lee S, Kim B, Kim JO, Oh KT, et al (2017) Rabies virus-inspired silica-coated gold nanorods as a photothermal therapeutic platform for treating brain tumors. Advanced materials (Deerfield Beach, Fla) 29(13)
113. Zhang X, Xi Z, Machuki JO, Luo J, Yang D, Li J et al (2019) Gold cube-in-cube based oxygen nanogenerator: a theranostic nanoplatform for modulating tumor microenvironment for precise chemo-phototherapy and multimodal imaging. ACS Nano 13(5):5306–5325
114. Li X, Zhang Y, Fu M, Tang Y, Yin S, Ma Z et al (2019) Using a graphene-polypolyelectrolyte complex reducing agent to promote cracking in single-crystalline gold nanoplates. ACS Appl Mater Interfaces 11(44):41602–41610
115. Ruan S, Xie R, Qin L, Yu M, Xiao W, Hu C et al (2019) Aggregate nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment. Nano Lett 19(11):8318–8332
116. Herbst RS, Soria J, Kowanetz M, Fine GD, Hamid O, Gordon MS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567
117. Jing Z, Li M, Wang H, Yang Z, Zhou S, Ma J et al (2021) Gallic acid-gold nanoparticles enhance radiation-induced cell death of human glioma U87 cells. IUBMB Life 73(2):398–407
118. Huang A, Jiang G, Song QX, Gu X, Hu M, Wang XL et al (2017) Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis. Nat Commun 8:15144
119. Wang Z, Liang P, He X, Wu B, Liu Q, Xu Z et al (2018) Etoposide loaded layered double hydroxide nanoparticles reversing chemoresistance and eradicating human glioma stem cells in vitro and in vivo. Nanoscale 10(27):13106–13121
120. Sanchez-Fernandez A, Pena-Paras L, Vidaltamayo R, Cue-Sampedro R, Mendoza-Martinez A, Zomosa-Signoret VC et al (2014) Synthesis, characterization, and in vitro evaluation of cytotoxicity of biomaterials based on halloysite nanotubes. Materials (Basel) 7(12):7770–7780
121. Zhao J, Li D, Ma J, Yang H, Chen W, Cao Y et al (2021) Increasing the accumulation of aptamer MSHV-1 and verapamil conjugated silver nanoparticles in tumor cells to enhance the radiosensitivity of glioma. Nanotechnology 32(14):145102
122. Zhang Y, Fu X, Jia J, Wikerholm T, Xi K, Kong Y et al (2020) Globlosta-
toma therapy using codelivery of cisplatin and glutathione peroxidase
targeting siRNA from iron oxide nanoparticles. ACS Appl Mater Inter-
faces 12(39):43408–43421
123. Sukumar UK, Bose RJC, Malhotra M, Babikir HA, Afjei R, Robinson E et al (2019) Intransal delivery of targeted polyfunctional gold-iron oxide
nanoparticles loaded with therapeutic microRNAs for combined thera-
estic multimodality imaging and presensitization of globolastoma to
temozolomide. Biomaterials 218:119342
124. Sallem F, Haji R, Vervander-Fasseur D, Nury T, Maurizi L, Boudon J et al (2019) Elaboration of trans-seresaterol derivative-loaded superpara-
magnetic iron oxide nanoparticles for glioma treatment. Nanomaterials
(Basel) 9(2)
125. Saalik P, Lingasamy P, Toome K, Mastandrea I, Rousso-Noori L, Tobi A
Mishra MK, Gupta J, Gupta R (2020) Self-assemble amphiphilic PEO-
126. Song HT, Hoang NH, Yun JM, Park YJ, Song EH, Lee ES et al (2016)
127. Cheng CC, Sun YT, Lee AW, Huang SY, Fan WL, Chiao YH et al (2020)
128. Wu Y, Xiao Y, Huang Y, Xu Y, You D, Lu W et al (2019) Rod-shaped
129. Authimoolam SP, Lakes AL, Puleo DA, Dziubla TD (2016) Layer-by-layers
130. Lobling TI, Haataja JS, Synatschke CV, Schacher FH, Muller M, Hanisch A
131. Sun P, Xiao Y, Di Q, Ma W, Ma X, Wang Q et al (2020) Transferrin receptor-
132. Chen Y, Zhang L, Liu Y, Tan S, Qu R, Wu Z et al (2018) Preparation of PGA-
133. Mandal A, Bishr R, Rupenthal ID, Mitra AK (2017) Polymeric micelles for
targeting siRNA from iron oxide nanoparticles. ACS Biomater Sci Eng
134. Buhlerie E, Vogtle F (1978) “Cascade” and “nonskid-chain-like” syntheses
135. Janaszewska A, Lazniewska J, Trzepinski P, Marcinkowska M, Klajnert-
136. Chauhan AS (2018) Dendrimers for drug delivery. Molecules 23(4)
137. Zhu Y, Liu C, Pang Z (2019) Dendrimer-based drug delivery systems for
brain targeting. Biomolecules 9(12)
138. Li J, Liang H, Liu J, Wang Z (2018) Poly (amidoamine) (PAMAM) dend-
139. Janaszewska A, Lazniewska J, Trzepinski P, Marcinkowska M, Klajnert-
140. Lobblo M, Haataja JS, Synatschke CV, Schacher FH, Muller M, Hanisch A
et al (2014) Hidden structural features of multicompartment micelles
revealed by cryogenic transmission electron tomography. ACS Nano
8(11):13301–13310
141. Xing Y, Zhou Y, Zhang Y, Zheng X, Deng X, Dong C et al (2020) Fabrication
of Au QDs@rGO nanocarriers for tumor-targeting drug delivery. J Mater Chem B 8(10):1527–1536
142. Apartsin E, Knauer N, Arkhipova V, Pashkina E, Poletaeva J, Aktanova A, Poletaeva J
143. Lin Y, Xu J, Lan H (2019) Tumor-associated macrophages in TME: biological roles and clinical therapeutic applications. J Hematol Oncol 12(1):76
144. Sharma A, Liaw K, Sharma R, Spriggs T, Appiani La Rosa S, Kannan S et al (2020) Dendrimer-mediated targeted delivery of rapamycin to tumor-associated macrophages improves systemic treatment of glioblastoma. J Neuroinflammation 17(1):23
145. Kim JH, Kim YK, Arash MT, Hong SH, Lee JH, Kang BN et al (2012) Galactosylation of chitosan-graft-spermine as a gene carrier for
hepatocyte targeting in vitro and in vivo. J Nanosci Nanotechnology
12(7):5718–5718
146. Lu L, Zhao X, Fu T, Li K, He Y, Luo Z et al (2020) An iRGD-conjugated prodrug micelle with blood-brain barrier penetrability for anti-
glioma therapy. Biomaterials 230:119666
147. Ran D, Mao J, Shen Q, Xie C, Zhan C, Wang R et al (2017) GPR78 ena-
abled micelle-based glioma targeted drug delivery. J Control Release 255:120–131
148. Shi H, Sun S, Xu H, Zhao Z, Han Z, Jia J et al (2020) Combined delivery of
temozolomide and siPLK1 using targeted nanoparticles to enhance temozolomide sensitivity in glioma. Int J Nanomedicine
15:3347–3362
151. Janaszewska A, Lazniewska J, Trzepinski P, Marcinkowska M, Klajnert-
152. Oliveira JM, Sousa N, Mano JF, Reis RL (2010) Dendrimers and deriva-
tives as a potential therapeutic tool in regenerative medicine strategies
- a review. Prog Polym Sci 15:1163–1194
153. Huang D, Wu D (2018) Biodgradable dendrimers for drug delivery.
Mater Sci Eng C Mater Biol Appl 90:713–727
154. Buhlerie E, Vogtle F (1978) “Cascade” and “nonskid-chain-like” syntheses
of molecular cavity topologies. Synthesis 2:155–158
155. Tomalia DBH, Dewald J, Hall M, Kallos G, Martin S, Rocek J, Ryder J, Smith P (1985) A new class of polymers: STARBURST®-dendritic macro-
156. Spataro G, Malecaze F, Turrin CO, Soler V, Duhayon C, Elena PP et al
157. Zhu Y, Liu C, Pang Z (2019) Dendrimer-based drug delivery systems for
targeting. Biomolecules 9(12)
158. Li J, Liang H, Liu J, Wang Z (2018) Poly (amidoamine) (PAMAM) dend-
159. Janaszewska A, Lazniewska J, Trzepinski P, Marcinkowska M, Klajnert-
160. Zhou Z, Tang J, Sun Q, Murdoch WJ, Shen Y (2015) A multifunctional
PEG-PLL drug conjugate forming rod-like-responsive nanoparticles for
intracellular drug delivery. J Mater Chem B 3(38):7594–7603
161. Apartsin E, Knauer N, Arkhipova V, Pashkina E, Poletaeva J, Aktanova A, Poletaeva J
162. Zhou Z, Tang J, Sun Q, Murdoch WJ, Shen Y (2015) A multifunctional
PEG-PLL drug conjugate forming rod-like-responsive nanoparticles for
intracellular drug delivery. J Mater Chem B 3(38):7594–7603
163. Chauhan AS (2018) Dendrimers for drug delivery. Molecules 23(4)
164. Peng Y, Huang J, Xiao H, Wu T, Shuai X (2018) Codelivery of temozolo-
165. Buhlerie E, Vogtle F (1978) “Cascade” and “nonskid-chain-like” syntheses
of molecular cavity topologies. Synthesis 2:155–158
166. Chauhan AS (2018) Dendrimers for drug delivery. Molecules 23(4)
167. Zhao J, Zhang B, Shen S, Chen J, Zhang Q, Jiang X et al (2015) CRECA
peptide-conjugated dendrimer nanoparticles for glioblastoma multi-
168. Janaszewska A, Lazniewska J, Trzepinski P, Marcinkowska M, Klajnert-
169. Chauhan AS (2018) Dendrimers for drug delivery. Molecules 23(4)
168. Chung EJ, Cheng Y, Morshed R, Nord K, Han Y, Wegscheid ML et al (2014) Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials 35(4):1249–1256

169. Uram L, Markowicz J, Misierak M, Filipowicz-Rachwał A, Wolowiec S, Waluty-Rode E (2020) Celyceoxib substituted biotinylated poly(alkyamine) G3 dendrimer as potential treatment for tectozolomide-resistant glioma therapy and anti-nematode agent. Eur J Pharm Sci 152:105439

170. Lu Y, Han S, Zheng H, Ma R, Ping Y, Zou J et al (2018) A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system. Int J Nanomed 13:5937–5952

171. Gao S, Li J, Jiang C, Hong B, Hao B (2016) Plasmid pORF-NTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer. Drug Des Devel Ther 10:1–11

172. Liaw K, Sharma R, Sharma A, Salazar S, Appiani La Rosa S, Kannan RM (2021) Systemic dendrimer delivery of triptolide to tumor-associated macrophages improves anti-tumor efficacy and reduces systemic toxicity in glioblastoma. J Control Release 329:434–444

173. Han S, Zheng H, Lu Y, Sun Y, Huang A, Fei W et al (2018) A novel synergistic targeting strategy for glioma therapy employing borneol combination with angiop-2-modified, DOX-loaded PAMAM dendrimer. J Drug Target 26(1186–94

174. Zhang H, Zhai Y, Wang J, Zhai G (2016) New progress and prospects: the application of nanogel in drug delivery. Mater Sci Eng C Mater Biol Appl 60:560–568

175. Ahmed S, Alharek H, Migent N (2020) Advancement in nanogel formulations provides controlled drug release. Int J Pharm 584:119435

176. Torres-Martinez A, Angulo-Facho CA, Galindo F, Miravet JF (2019) Liposome-encapsulated molecular nanogels. Langmuir 35(41):13375–13381

177. Feng L, Wang JA, Li SX, Tolia G, Hao J, Choo DI (2014) Assessment of PLGA-PEG-PLGA copolymer hydrogel for sustained drug delivery in the ear.Curr Drug Deliv 11(2):279–286

178. Hamidi M, Azadi A, Rafiei P (2008) Hydrogel nanoparticles in drug application of nanogel in drug delivery. Mater Sci Eng C Mater Biol Appl 28:116782

179. El-Feky GS, El-Banna ST, El-Bahy GS, Abdelrazek EM, Kamal M (2017) Alginate coated chitosan nanogel for the controlled topical delivery of Silver sulfadiazine. Carbohydr Polym 177:194–202

180. Borah PK, Das AS, Mukhopadhyay R, Sarkar A, Duay RK (2020) Macromolecular design of folic acid functionalized amlyopectin-albumin core-shell nanogels for improved physiological stability and colon cancer cell targeted delivery of curcumin. J Colloid Interface Sci 580:561–572

181. Pedrosa SS, Pereira P Correia A, Gama FM (2017) Targetability of hyaluronic acid-modified smart drug delivery systems. Acta Biomater 92:1–18

182. Hajebi S, Rabiee N, Bagherzadeh M, Ahmadi S, Rabiee M, Roghani-Mamaqani H et al (2019) Stimulus-responsive polymeric nanogels as targeted drug delivery vehicles for cancer therapy. Adv Drug Deliv Rev 244( Pt A):108–121

183. Wang H, Wang X, Xie C, Zhang M, Ruan H, Wang S et al (2018) Nanodisk-based glioma-targeted drug delivery enabled by a stable glycopeptide. J Control Release 284:26–38

184. Ding Y, Yang W, Niu P, Li X, Chen Y, Li Z, Liu Z, An Y, Liu Y, Shen W, Shi L (2020) Investigating the EPR effect of nanomedicines in human renal tumors via ex vivo perfusion strategy. Nano Today 35

185. Danhier F (2016) To exploit the tumor microenvironment. Since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release 244( Pt A):108–121

186. Wang H, Wang X, Xie C, Zhang M, Ruan H, Wang S et al (2018) Nanodisk-based glioma-targeted drug delivery enabled by a stable glycopeptide. J Control Release 284:26–38

187. Rijkema SJ, Langens S, van der Kolk MR, Toebes BJ, Wilson DA (2020) Modular approach to the functionalization of polymersomes. Biomacromol 21(5):1835–1846

188. Wang R, Degirmenci V, Xin H, Li Y, Wang L, Chen J et al (2018) PEI-coated Fe3O4 nanoparticles enable efficient delivery of therapeutic siRNA targeting REST into Glioblastoma cells. Int J Mol Sci 19(8)

189. Kim H, Kim A, Miyata K, Kataoka K (2016) Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Deliv Rev 104:61–77

190. Chen H, Shi Y, Sun L, Ni S (2020) Electrospun composite nanofibers with all-trans retinoic acid and MWCNTs-OH against cancer stem cells. Life Sci 258:118152

191. Caverzán MD, Beaugé L, Chesta CA, Palacios RE, Ibarra LE (2020) Photodynamic therapy of Glioblastoma cells using doped conjugated polymer nanoparticles; an in vitro comparative study based on redox status. J Photochem Photobiol B Biol 212:112045

192. Liu Y, Tan J, Zhang Y, Zhuang J, Ge M, Shi B et al (2018) Visualizing glioma margins by real-time tracking of gamma-glutamyltranspeptidase activity. Biomaterials 173:1–10

193. Luo S, Zhang E, Su Y, Cheng T, Shi C (2011) A review of NIR dyes in cancer targeting and imaging. Biomaterials 32(29):7127–7138

194. Qian W, Qian M, Wang Y, Huang J, Chen J, Ni L et al (2018) Combination glioma therapy mediated by a dual-targeted delivery system constructed using OMCN-PEG-Pep22/DOX. Small 14(42):e1801905

195. Zhao M, Liang C, Li A, Chang J, Wang H, Yan R et al (2010) Magnetic paclitaxel nanoparticles inhibit glioma growth and improve the survival of rats bearing glioma xenografts. Anticancer Res 30(6):2217–2223

196. Lu Q, Dai X, Zhang P, Tan X, Zhong Y, Yao C et al (2018) Fe3O4@Au composites of magnetic nanoparticles modified with cetyltrimethyl for targeted
magneto-photothermal therapy of glioma cells. Int J Nanomed 13:2491–2505
211. Liu D, Yang F, Xiong F, Gu N (2016) The smart drug delivery system and its clinical potential. Theranostics 6(9):1306–1323
212. Klopfleisch R (2016) Macrophage reaction against biomaterials in the mouse model—phenotypes, functions and markers. Acta Biomater 43:3–13
213. Anderson JM, Rodriguez A, Chang DT (2008) Foreign body reaction to biomaterials. Semin Immunol 20(2):86–100

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.